TRANSFORMING THE LIVES OF PATIENTS WITH AUTOIMMUNE DISEASES AND CANCER Making Cell Therapies Accessible to AllTM Corporate Presentation February 2026 © 2026 Fate Therapeutics. All rights reserved. - 1 - Q1 2026 Business Updates & Near-Term Objectives Competitively positioned to accelerate clinical stage development | | Milestones Achieved | Near Term Next Steps | | --- | --- | --- | | | ✓ 15 lupus patients enrolled with 7 initial sites, with 16 | Complete Phase 1 SLE cohort enrollment by mid-2026 | | Autoim ...

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Ca ...

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for patients with HLA types A*01:01 and A*03:01 Plans to initiate Phase 1 study of both TSC-102 candidates in the second half of 2026 WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell re ...

Group 1 - Brainstorm Cell Therapeutics Inc. has announced a second definitive agreement for an additional $1 million strategic private placement [1] - The total capital raised by the company in February 2026 has reached $2 million [1]

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported an EPS of -$1.22, missing estimates and indicating financial challenges. The company's revenue fell significantly short of expectations, with actual revenue at $121,000 versus an estimated $1.39 million. Despite financial hurdles, Celldex is advancing in clinical trials, with Phase 3 studies for chronic spontaneous urticaria fully enrolled and more studies underway. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a biotechnology company focused on developing tre ...

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quarter Highligh ...

Earnings SnapshotOn Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the consensus of $391.92 million.The sales fell 33% year over year, primarily reflecting $273.8 million less in net product revenue of Elevidys as a result of lower volume following the company’s decision to suspend shipments of Elevidys to non-ambulatory patients in the U.S. in June 2025.Management TransitionIn an SEC filing ...

While the market was melting down on Monday, Rev calmly wrote 5 Stocks I’m Buying While the Crowd Focuses on AI Disaster . You should read the whole thing over on TheStreet Pro , because I’m only going to share three of Rev’s five picks.So, let’s look for the bullish side of the AI trade. Today, I’m sharing four stocks that AI will help, not hurt.So, what’s Rev’s game plan? As always, Rev is a trader. He thinks the best trades come from stock selection and timing. And that’s what he’s doing. Picking stocks ...

Negative P/E ratio of -29.54 indicates current unprofitability.Low debt-to-equity ratio of 0.12 suggests a conservative approach to debt.High price-to-sales ratio of 183.24 reflects significant market expectations for future growth.ACLX (NASDAQ:ACLX), is currently navigating through financial challenges, highlighted by its negative price-to-earnings (P/E) ratio of -29.54, signaling that the company is not profitable at this time. Despite this, ACLX exhibits a low debt-to-equity ratio of 0.12, indicating a c ...

Core Viewpoint - Sarepta Therapeutics CEO Douglas Ingram will retire by the end of 2026 or upon the appointment of a successor, following a challenging year for the company marked by significant setbacks related to its gene therapy product, Elevidys [1]. Company Developments - The company has initiated a search for a new CEO after Ingram's announcement of his retirement [1]. - Sarepta faced a tumultuous 2025, with Elevidys linked to the deaths of two patients, leading to a request from the U.S. Food and Drug Administration (FDA) to voluntarily halt shipments of the therapy [1]. - The FDA is currently investigating the deaths associated with Elevidys, which has resulted in the therapy carrying the most serious safety warning and stringent monitoring requirements post-treatment [1]. Financial Impact - Sarepta announced 500 job cuts and halted the development of several gene therapies for limb-girdle muscular dystrophy in response to the challenges faced [1]. - The company's shares fell by 82% last year, reflecting the negative market reaction to the issues surrounding Elevidys [1]. - Following the announcement of Ingram's retirement, the stock was down approximately 4% in after-market trading [1].